TRASTUZUMAB PAMIRTECAN
UNII WPL7XBK5KU

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Pamirtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) WPL7XBK5KU.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2792722-57-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

WPL7XBK5KU

CAS Registry Number

2792722-57-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRASTUZUMAB PAMIRTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188319

National Cancer Institute reference terminology for clinical and research data.

INN ID

13179

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-147

Identifier assigned by the United States Adopted Names Council.

Substance Type

Trastuzumab Pamirtecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Pamirtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Trastuzumab Pamirtecan

Common Names & Synonyms

DB 1303 [WHO-DD]

H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of L-cysteinyl residues 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with (3RS)-1-[(7S)-7-benzyl-1-{[(1R,3R)-3-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}cyclobutyl]oxy}-3,6,9,12,15-pentaoxo-2,5,8,11,14-pentaazaicosan-20-yl]-2,5-dioxopyrrolidin-3-yl (pamirtecan) groups

Immunoglobulin G1 [de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal DB-1303 γ1-chain), disulfide with human-Mus musculus monoclonal DB-1303 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[[cis-3-[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]cyclobutyl]oxy]methyl]glycinamide

TRASTUZUMAB PAMIRTECAN [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody,conjugated on an average of eight cysteinyl residues to pamirtecan, comprising a linker and a camptothecin derivative (exatecan)

trastuzumab pamirtecan [INN]